Gamma camera probe developer Neoprobe of Dublin, OH, will meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2010 to discuss its plans to begin clinical testing of its RIGScan cancer-detecting technology.
If the FDA approves the company's plans, Neoprobe will submit an investigational new drug application. With the FDA's clearance, Neoprobe would then begin RIGScan clinical trials on humans.
RIGScan attaches itself to cancerous cells in the body, which can be identified by a handheld radiation detection device. A cancer patient is injected with the drug before surgery, so the device can direct a surgeon to cancerous tissue in the patient's body.
Related Reading
Neoprobe scores grant, November 3, 2010
Neoprobe wraps up pre-NDA meeting, October 7, 2010
Neoprobe revenues, losses grow in Q2, August 10, 2010
Neoprobe expects Q2 revenue gains, July 15, 2010
Neoprobe secures $1M grant, June 25, 2010
Copyright © 2010 AuntMinnie.com
